Table 2 Distribution of pCR rates according to tumor phenotype.

From: HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment

 

pCR, n (%)

p-value

Primary BC phenotype

 

<0.001a

HR+ /HER2− (105)

10 (9.5)

TN (156)

60 (38.5)

HER2+ (185)

85 (45.9)

  1. BC, breast cancer, HR+ hormone-receptor positive, HER2– HER2-negative, TN triple-negative, HER2+ HER2-positive, pCR pathologic complete response.
  2. aχ2 test.
Back to article page